Spark Therapeutics, Inc. Common Stock
ONCE
ONCE was delisted on the 16th of December, 2019.
157 hedge funds and large institutions have $1.54B invested in Spark Therapeutics, Inc. Common Stock in 2018 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 59 increasing their positions, 52 reducing their positions, and 34 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
13% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 52
11% less funds holding
Funds holding: 176 → 157 (-19)
29% less capital invested
Capital invested by funds: $2.17B → $1.54B (-$634M)
56% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 34
59% less call options, than puts
Call options by funds: $3.84M | Put options by funds: $9.45M
Top Buyers
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$57.4M |
| 2 |
D.E. Shaw & Co
New York
|
+$18.5M |
| 3 |
Goldman Sachs
New York
|
+$16.8M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$13.4M |
| 5 |
EC
EcoR1 Capital
San Francisco,
California
|
+$13M |
Top Sellers
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$100M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$39.4M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$25M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
-$18.9M |
| 5 |
AC
Armistice Capital
New York
|
-$12.4M |
ONCE Hedge Fund Activity: Q4 2018 in Review
157 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Spark Therapeutics, Inc. Common Stock (ONCE) for Q4 2018, worth a combined $1.54B — down 29% from $2.17B a quarter earlier.
Sellers outnumbered buyers: 34 funds closed out of ONCE and 15 opened new positions — a net loss of 19 holders — while 52 trimmed existing stakes and 59 added.
The largest buyer was PFM Health Sciences, adding an estimated $57.4M. The largest seller was Wellington Management Group, cutting an estimated $100M.
- 157 institutional investors held Spark Therapeutics, Inc. Common Stock (ONCE) as of Q4 2018, down from 176 in Q3 2018.
- Funds reported $1.54B of Spark Therapeutics, Inc. Common Stock stock for Q4 2018, down 29% quarter-over-quarter.
- 15 funds opened new Spark Therapeutics, Inc. Common Stock positions in Q4 2018 and 34 closed out, a net change of -19 holders.
- The largest Spark Therapeutics, Inc. Common Stock buyer in Q4 2018 was PFM Health Sciences, an estimated $57.4M added.
- The largest Spark Therapeutics, Inc. Common Stock seller in Q4 2018 was Wellington Management Group, an estimated $100M sold.
Based on aggregated 13F filings for Q4 2018.